With Canadian biologic drug sales growing at a rate of 13 per cent annually over the last 10 years, plan sponsors are looking for ways to manage the related costs — and the introduction of biosimilars may help. At a recent Pfizer-sponsored webinar hosted by Benefits Canada, “Evidence to Policy — Biosimilar Transitioning in Canada,” two […]
A recent Telus Health comparison of a drug’s cost effectiveness when calculated from the private versus the public-payer perspective demonstrated clearly that the private-payer perspective matters when assessing the value of a medication, explained Dr Nina Lathia, pharmacist, and health economist, at Benefits Canada’s Face to Face Drug Plan Management Forum on Dec. 9, 2020. […]